Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AgomAb Therapeutics NVAGMB +1.96%14 Cash Ratio is 12.55 as of Jun. 2026, which is 12% above its 10-year median of 11.25. GuruFocus rates AGMB with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 1,328 Biotechnology companies, AgomAb Therapeutics NV ranks better than 85.62% on this metric.
AgomAb Therapeutics NV has a Cash Ratio of 12.55. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for AgomAb Therapeutics NV's Cash Ratio or its related term are showing as below:
AGMB'
s Cash Ratio Range Over the Past 10 Years
Min: 1.59 Med: 11.25 Max: 18.79
Current: 12.55
During the past 5 years, AgomAb Therapeutics NV's highest Cash Ratio was 18.79. The lowest was 1.59. And the median was 11.25.
AGMB's Cash Ratio is ranked better than 85.62% of 1328
companies
in the Biotechnology industry
Industry Median: 3.03
vs AGMB: 12.55
AgomAb Therapeutics NV (NAS:AGMB) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, AgomAb Therapeutics NV's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AgomAb Therapeutics NV Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AgomAb Therapeutics NV's Cash Ratio distribution charts can be found below:
* The bar in red indicates where AgomAb Therapeutics NV's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AgomAb Therapeutics NV (AGMB) has a Cash Ratio of 12.55 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on AgomAb Therapeutics NV and its competitors. This is 12% above median its historical median of 11.25. Over the past decade, AgomAb Therapeutics NV's Cash Ratio has ranged from 1.59 to 18.79. According to the industry distribution chart, AgomAb Therapeutics NV ranks #191 out of 1328 companies in the Biotechnology industry, placing it in the top 14.4%.
Is AgomAb Therapeutics NV's Cash Ratio too high?
AgomAb Therapeutics NV's current Cash Ratio of 12.55 is 12% above median its 10-year median of 11.25. Over the past 10 years, this metric has ranged from a low of 1.59 to a high of 18.79. The Biotechnology industry median Cash Ratio is 3.03. AgomAb Therapeutics NV's value of 12.55 is 314.2% above this industry median. Based on the distribution chart, AgomAb Therapeutics NV ranks #191 out of 1328 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, AgomAb Therapeutics NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does AgomAb Therapeutics NV's Cash Ratio compare to CRMD and RGNX?
According to the Biotechnology industry distribution chart, AgomAb Therapeutics NV ranks #191 out of 1328 companies for Cash Ratio. This places AgomAb Therapeutics NV in the top 14% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 3.03. AgomAb Therapeutics NV's value of 12.55 is 314.2% above this benchmark. Historically, AgomAb Therapeutics NV's own Cash Ratio has ranged from 1.59 to 18.79 over the past decade. While the company's 10-year median is 11.25 vs. the industry median of 3.03, AgomAb Therapeutics NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 3.03, based on 1,328 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AgomAb Therapeutics NV's current Cash Ratio of 12.55 is 314.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on AgomAb Therapeutics NV and its competitors. For the Biotechnology industry, the median Cash Ratio is 3.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AgomAb Therapeutics NV's current Cash Ratio is 12.55, which is 12% above median its own 10-year median of 11.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AgomAb Therapeutics NV stock overvalued right now?
AgomAb Therapeutics NV (AGMB) has a current Cash Ratio of 12.55. The current Cash Ratio is 12.55, which is 12% above median its 10-year median of 11.25 and 314.2% above the Biotechnology industry median of 3.03. AgomAb Therapeutics NV's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For AgomAb Therapeutics NV (AGMB), the current Cash Ratio is 12.55 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
14GF Score
Get the complete analysis for AGMB
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AGMB has been successfully added to your 
